Brosius Mark sold $25K of ISRG

Barclays initiated coverage on 26 medical device makers, rating Stryker (SYK) and Abbott Laboratories (ABT) as Overweight. Analyst Christopher Pasquale cited compelling valuations and a potential stabilization of revenue as catalysts. Price targets were set for several companies, including SYK at $375 and ABT at $120.

Intuitive Surgical (ISRG) received CE mark approval for its da Vinci 5 system in cardiac procedures, including coronary artery bypasses and thoracoscopic cardiotomy. The company aims to expand its robotic-assisted cardiac surgery offerings in Europe, with a dedicated team and partnerships with select centers. ISRG previously received FDA clearance for cardiac use in January.

Intuitive Surgical received CE mark approval for its da Vinci surgical robot to perform cardiac procedures in adults, including minimally invasive coronary artery bypass. This approval allows Intuitive to compete with rivals Medtronic and Johnson & Johnson in the surgical robotics space. The company aims to expand its cardiac surgery offerings globally, following FDA clearance for cardiovascular procedures in January.

Intuitive Surgical (ISRG) received CE mark approval for its da Vinci SP system for transvaginal gynecological procedures in Europe, expanding its use in women's health. The system, already approved for other surgeries, allows single-incision operations, potentially improving recovery and outcomes. It is also approved in the US, Japan, and Korea.

Intuitive (ISRG) received CE mark approval for transvaginal gynecologic procedures using the da Vinci SP system in Europe, expanding its applications. The approval allows for less invasive options and potentially better recovery experiences. The system is already approved in the US, Japan, and Korea for various procedures.

Goldman Sachs projects 6.5 million humanoid robots will be shipped globally by 2035, representing a $138 billion market opportunity. Companies like Tesla, TSMC, Teradyne, and NVIDIA are positioned to benefit, with some already showing significant revenue growth. A potential AI slowdown is cited as a risk to this forecast.